Vanguard Capital Management
PASG icon

Vanguard Capital Management’s Passage Bio PASG Stock Holding History

Vanguard Capital Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$327K Sell
72,741
-41,223
-36% -$193K ﹤0.01% 3736
2026
Q2 		$556K Hold
113,964
– – ﹤0.01% 3702
2026
Q1 		$895K Buy
+113,964
New +$1.18M ﹤0.01% 3574

Other funds holding PASG

Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $13.7B AUM 40.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Deltec Asset Management
Deltec Asset Management New York $642M AUM 16.66% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

Vanguard Capital Management's PASG Position: Q3 2026 in Review

Vanguard Capital Management reduced its Passage Bio (PASG) stake by 36% in Q3 2026, selling an estimated $193K and leaving 72,741 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #3736.

Vanguard Capital Management first reported a position in PASG in Q1 2026 and has held it in 3 quarters since. The position peaked at $895K in Q1 2026. 20 funds tracked by Wall St. Rank hold PASG as of Q3 2026.

  • Vanguard Capital Management held 72,741 shares of Passage Bio worth $327K as of Q3 2026.
  • Vanguard Capital Management sold 41,223 Passage Bio shares in Q3 2026, an estimated $193K.
  • Passage Bio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3736 holding.
  • Vanguard Capital Management first reported a position in Passage Bio in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Passage Bio position peaked at $895K in Q1 2026.
  • 20 funds tracked by Wall St. Rank held Passage Bio as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.